Publication: Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: A randomized placebo-controlled pilot study
Issued Date
2013-07-01
Resource Type
ISSN
10600280
Other identifier(s)
2-s2.0-84880069235
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Annals of Pharmacotherapy. Vol.47, No.7-8 (2013), 921-932
Suggested Citation
Suwimon Yeephu, Chuthamanee Suthisisang, Saithip Suttiruksa, Pradit Prateepavanich, Patchara Limampai, Irwin Jon Russell Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: A randomized placebo-controlled pilot study. Annals of Pharmacotherapy. Vol.47, No.7-8 (2013), 921-932. doi:10.1345/aph.1R725 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/32270
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: A randomized placebo-controlled pilot study
Other Contributor(s)
Abstract
BACKGROUND: Data from an open-label trial suggest that mirtazapine might prove useful in treatment of fibromyalgia syndrome (FMS). OBJECTIVE: To obtain preliminary efficacy data of mirtazapine for estimation of sample size requirements for a Phase 2 clinical trial in FMS. METHODS: This 13-week randomized controlled trial compared the effects of mirtazapine 15 mg/day, mirtazapine 30 mg/day, and placebo in 40 patients with FMS. The primary outcomes were change in Pain Visual Analog Scale (PVAS) and proportion of pain responders (≥30% PVAS reduction). Secondary outcomes included scores from the Jenkins Sleep Scale (JSS), Patient Global Impression of Change (PGIC), Fibromyalgia Impact Questionnaire (FIQ), Hamilton Depression Rating Scale (HAM-D), Patient Global Assessment, and self-reported adverse events. RESULTS: Significant within-group PVAS reductions from baseline were observed in all 3 groups, with the greatest improvement in the mirtazapine 30-mg group (p < 0.005); between-group difference was not significant. The proportion of pain responders did not meet significance criteria (66.67% for mirtazapine 30 mg, 50% for mirtazapine 15 mg, 41.67% for placebo). Significant within-group improvement in JSS scores was seen for mirtazapine 30 mg (p < 0.01) and mirtazapine 15 mg (p < 0.05). Between-group comparison achieved significance for JSS item 3, waking several times per night (p < 0.05). On the PGIC, 72.73% felt better with both mirtazapine dosages compared with 50% for placebo. Withingroup FIQ responses indicated improvement in only mirtazapine-treated groups, whereas within-group improvement for HAM-D and Patient Global Assessment was observed in all groups. Based on our findings, the sample size requirement (80% power, 5% type I error) should be 83 per group to detect PVAS change difference between mirtazapine 30 mg and placebo. Common mirtazapinerelated adverse events were increased appetite and weight gain. CONCLUSIONS: Patients with FMS taking mirtazapine exhibited within-group significant improvement in most of the measured outcomes. Between-group analysis was predictably compromised by the small sample size. Mirtazapine was well tolerated. Further study with a larger sample size is likely to be useful. © 1967-2013 Harvey Whitney Books Co. All rights reserved.